All News
ACR23 – Day 3 Report
These year’s annual ACR Convergence has been a success with the return of an insanely active Poster Hall! F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be.
Read Article
Should We Change How We Prescribe Methotrexate?
For as long as I can remember, methotrexate has been the anchor drug treatment of rheumatoid arthritis. We also know it has limited oral bioavailability at doses greater than 15mg. There are subcutaneous forms that offer better bioavailability, but its subcutaneous nature can sometimes sway patients away from trying it in addition to its higher cost. Split dosing of methotrexate can be a solution to attain higher bioavailability; however, its effect on clinical efficacy is unknown.
Read Article
L20 @ #ACR23
New therapy on the horizon for RA pts that failed MTX?
⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL
➡️ placebo-controlled, phase III trial, 24w
👉at wk 24, PBO pts switched to drug arm for 24 more wks
➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Interesting look into autoantibody profile of rheumatic disease-ILD compared to IPF
Identified 7 ab in RD-ILD, emphasizing lack of autoimmunity in IPF
Different mechanisms of damage and progression based on ab profile?
@RheumNow #ACR23 Abs#2572 https://t.co/5rtXnOe9oJ
Robert B Chao, MD ( View Tweet)
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/XvNMXAFkWe https://t.co/HVvBLhqe8H
Dr. John Cush RheumNow ( View Tweet)
Effective Treatments for Rheumatoid Arthritis ILD
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Read Article
Auricular vagal nerve stimulation did not meaningfully improve RA disease activity. Further research of the novel intervention is required in RA, Baker MC, #ACR23 @RheumNow https://t.co/agLtRKdDTf
Dr. Antoni Chan ( View Tweet)
🆕 2023 ACR Guidelines for Management of Interstitial Lung Disease (#ILD) in Systemic Autoimmune Rheumatic Diseases 🫁
🔸 Screening & Monitoring Recs
🔸 Treatment Guidelines ILD/RP-ILD
#RheumTwitter #PulmTwitter #MedTwitter #MedX https://t.co/JreVO0kgEf
Mithu Maheswaranathan, MD ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)
Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor.
46% flared
Seropositive- OR 2.0
NO association with mortality
-ICIs are safe to use in RA
-Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were generally safe, well tolerated with most TEAEs being mild to moderate. Effect seen in Week 1. Wu C, Late breaking Abst#L09 #ACR23 @RheumNow https://t.co/M29LYtEs9I
Dr. Antoni Chan ( View Tweet)
#ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study. https://t.co/d0ZBWDKZlB https://t.co/EdllyGUT1y
Dr. Rachel Tate ( View Tweet)
Rx of #inflammatory #arthritis with #glucocorticoids doesn’t seem to affect outcomes in #malignancy treated with #checkpoint #inhibitors. Good news as new or flaring inflammatory arthritis as an irAE can be severe. #ACR23 @RheumNow @ACRheum #1055 @CanRIO_Tweets https://t.co/tFIPcQq2X6
Janet Pope ( View Tweet)
Tapering ABA vs. stable dose ABA in RA
No diff in DAS28 remission at 2 years
But…
Only in patients receiving concomitant MTX
Those tapering ABA mono also experience higher functional important
Of note: not an RCT
@RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
Aurelie Najm ( View Tweet)
The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis.
Intervention included food delivery svc & probiotic shot
Limitations included study design issues such small sample size
#ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS
sheila ( View Tweet)
#ACRBest https://t.co/nx3bzhmeBW
Aurelie Najm ( View Tweet)
There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP
Dr. Antoni Chan ( View Tweet)
Synovial tissue histology correlates w/ several clinical parameters in early naive RA
Combination ohigh CD68 infiltrate
Fibrinoid Necrosis in tissue asso w/
-better DA reduction
-higher EULAR moderate/good resp
Included in a prediction model (AUC0.7)
@RheumNow #ACR23 ABST2483 https://t.co/2jCMSzV7ak
Aurelie Najm ( View Tweet)
Body mass is associated w/ ttmt response in RA
Data from RACAT & TEAR studies
TNFi > triple th in underweight gpe but not in overweight gpe
Similar result in gpe w/ low leptin levels
& low adipokine scores
True biology or confounding bias?
@RheumNow #ACR23 ABST2541 https://t.co/OhKj6QNaSa
Aurelie Najm ( View Tweet)